SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001445305-14-003554
Filing Date
2014-08-08
Accepted
2014-08-08 16:20:52
Documents
10
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20140630x10q.htm 10-Q 756435
2 EXHIBIT mrtx63014ex311.htm EX-31.1 11144
3 EXHIBIT mrtx63014ex312.htm EX-31.2 11874
4 EXHIBIT mrtx63014ex321.htm EX-32.1 7817
  Complete submission text file 0001445305-14-003554.txt   4617990

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20140630.xml EX-101.INS 720193
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20140630.xsd EX-101.SCH 31886
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20140630_cal.xml EX-101.CAL 55254
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20140630_def.xml EX-101.DEF 80930
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20140630_lab.xml EX-101.LAB 361815
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20140630_pre.xml EX-101.PRE 188667
Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 141027727
SIC: 2834 Pharmaceutical Preparations